Product NDC: | 44206-454 |
Proprietary Name: | Hizentra |
Non Proprietary Name: | HUMAN IMMUNOGLOBULIN G |
Active Ingredient(s): | .2 g/mL & nbsp; HUMAN IMMUNOGLOBULIN G |
Administration Route(s): | SUBCUTANEOUS |
Dosage Form(s): | LIQUID |
Coding System: | National Drug Codes(NDC) |
Product NDC: | 44206-454 |
Labeler Name: | CSL Behring AG |
Product Type: | PLASMA DERIVATIVE |
FDA Application Number: | BLA125350 |
Marketing Category: | BLA |
Start Marketing Date: | 20111003 |
Package NDC: | 44206-454-04 |
Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (44206-454-04) > 20 mL in 1 VIAL, SINGLE-DOSE (44206-454-92) |
NDC Code | 44206-454-04 |
Proprietary Name | Hizentra |
Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (44206-454-04) > 20 mL in 1 VIAL, SINGLE-DOSE (44206-454-92) |
Product NDC | 44206-454 |
Product Type Name | PLASMA DERIVATIVE |
Non Proprietary Name | HUMAN IMMUNOGLOBULIN G |
Dosage Form Name | LIQUID |
Route Name | SUBCUTANEOUS |
Start Marketing Date | 20111003 |
Marketing Category Name | BLA |
Labeler Name | CSL Behring AG |
Substance Name | HUMAN IMMUNOGLOBULIN G |
Strength Number | .2 |
Strength Unit | g/mL |
Pharmaceutical Classes | Human Immunoglobulin G [EPC],Passively Acquired Immunity [PE],Antigen Neutralization [MoA],Immunoglobulins [Chemical/Ingredient] |